CClinicalTrials.gg
CompletedNCT03445754TVS-PADUpdated Apr 1, 2026

Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function in PAD

An interventional study of TVS and Sham TVS in Peripheral Artery Disease, Endothelial Dysfunction and Autonomic Imbalance, sponsored by University of Oklahoma. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by University of Oklahoma · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Peripheral arterial disease (PAD) constitutes a major public health burden. The incidence of PAD increases with age and is associated with other comorbid cardiovascular disorders. Atherosclerosis which underlies PAD is associated with increased arterial stiffness and an enhanced inflammatory state as evidenced by increased levels of pro-inflammatory cytokines and markers. One the earliest signs of cardiovascular disease is endothelial dysfunction which is characterized by a decreased vasodilatory capacity of the vascular endothelium and this lesion predates the development of clinical atherosclerosis. Endothelial dysfunction has been shown to be widely prevalent in PAD. It is postulated that endothelial dysfunction is due to enhanced sympathetic drive, diminished parasympathetic drive, chronic inflammatory state all of which leads to reduced nitric oxide synthase activity in the vascular endothelium with subsequent loss of vasodilatory capacity. Studies have shown endothelial dysfunction to be reversible with pharmaco-therapeutic interventions, though these interventions are associated with their own adverse effects. Stimulation of Vagal nerve increases the parasympathetic activity while suppressing sympathetic drive, decreases inflammation and enhancing nitric oxide synthase activity. Recent experimental and clinical data suggest that low-level tragus nerve stimulation (by stimulating the auricular branch of the vagus nerve located at the tragus of the external ear) may produce the same desired neuromodulator effect compared to vagus nerve stimulation. It is however unknown if Transcutaneous Vagal Stimulation (TVS) would lead to improved endothelial function as measured by flow mediated dilatation (FMD) and laser speckle contrast imaging(LSCI), a non-invasive method of measuring endothelial function or decrease in arterial stiffness as measured by Pulse Wave Analysis (PWA), in patients with PAD. The objective of this study is to determine the impact of TVS on endothelial dysfunction as measured by FMD \& LSCI and arterial stiffness. Study population will include patients with established diagnosis of PAD. After performing baseline FMD, LSCI and PWA patients will be randomized to TVS and sham stimulation with cross over. The patient randomized to TVS stimulation will obtain stimulation for 1 hour followed by measurement of FMD,LSCI and PWA. There will be a washout period of at least 24 hours with patient crossing over to the other arms thus serving as their self-control.

02

Conditions studied

  • Peripheral Artery Disease
  • Endothelial Dysfunction
  • Autonomic Imbalance
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. peripheral arterial disease (PAD) - patients with an ankle-brachial index of \<0.9
  2. symptoms of intermittent claudication, rest pain, or minor tissue loss (Rutherford category I-V)

Exclusion criteria

Exclusion Criteria:

  1. patients with acute limb ischemia
  2. Patients with overt congestive heart failure / recent acute myocardial infarction (\< 3 months)
  3. Premenopausal women and post-menopausal women on hormone supplements.
  4. chronic inflammatory disease (systemic lupus erythematosus, rheumatoid arthritis, and Crohn's disease), or receiving therapy with steroids, cyclosporine, methotrexate or immunocompromised patients.
  5. unilateral or bilateral vagotomy
  6. Patients with bilateral upper extremity amputation
  7. pregnant patients
  8. prisoners
  9. end-stage renal disease.
  10. End-stage liver disease.
  11. patients with BMI>34
  12. Patients with upper extremity arterial disease
  13. history of recurrent vasovagal syncope, Sick sinus syndrome, 2nd- or 3rd-degree atrioventricular block (AV) block, prolonged first degree AV block.
  14. Refusal to sign a consent form.
  15. Significant hypotension from autonomic dysfunction
  16. Patients with pacemakers who have significant interaction with TVNS during testing
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Interventional Arm

    Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.

    Device: TVS

  • Sham comparator
    Control

    Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.

    Device: Sham TVS

Interventions

  • DeviceTVS

    Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour

  • DeviceSham TVS

    Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.

05

What researchers measure

Primary outcomes

  1. Flow mediated vasodilatation

    Flow mediated vasodilatation will be tested. A change in the maximal diameter of the brachial artery(in mm) will be assessed immediately(within 10 minutes) after TVNS/sham stimulation.

    Time frame: Change from baseline to post stimulation(within 10 minutes of stimulation) with TVS/Sham stimulation

Secondary outcomes

  1. Endothelial function in microcirculation

    LSCI based calculation of perfusion unit before and after TVS/Sham stimulation

    Time frame: Change from baseline to post stimulation(within 20-30 minutes of stimulation) with TVS/Sham stimulation

  2. Pulse wave analysis

    Arterial elasticity. Augmentation pressure (AP) will be calculated which is expressed as a percentage of the aortic pulse pressure (PP) which is the difference of systolic and diastolic BP(mm Hg).

    Time frame: Change from baseline to post stimulation(within 15-20 minutes) with TVS/Sham stimulation.

06

Study locations

1 site
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73117, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03445754
Lead sponsor
University of Oklahoma
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Dec 11, 2017
Primary completion
May 30, 2020
Completion
May 30, 2020
Last update
Apr 1, 2026

Study contacts

Tarun Dasari, MD, MPH
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion